ArticleBlood advances2025

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.

Mazyar Shadman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.